CRO

Pernix Therapeutics offers $4.9M for CMO Great Southern Laboratories

With a $4.9 million offer on the table, pharma company Pernix Therapeutics ($PTX) will acquire Houston CMO Great Southern Laboratories in deal that should be closed before month's end, according to a company statement. Once finalized, Pernix hopes the acquisition will improve its profit margins on generics, while laying the foundation for developing future over-the-counter and prescription products, according to the pharma company. Great Southern earns its keep by manufacturing liquids, tablets, capsules, ointments and creams, generating about $12 million in revenues for fiscal 2011. Statement